A. Bex Et Al. , "Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial," JAMA Oncology , vol.5, no.2, pp.164-170, 2019
Bex, A. Et Al. 2019. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncology , vol.5, no.2 , 164-170.
Bex, A., Mulders, P., Jewett, M., Wagstaff, J., Van Thienen, J. V., Blank, C. U., ... Van Velthoven, R.(2019). Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncology , vol.5, no.2, 164-170.
Bex, Axel Et Al. "Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial," JAMA Oncology , vol.5, no.2, 164-170, 2019
Bex, Axel Et Al. "Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial." JAMA Oncology , vol.5, no.2, pp.164-170, 2019
Bex, A. Et Al. (2019) . "Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial." JAMA Oncology , vol.5, no.2, pp.164-170.
@article{article, author={Axel Bex Et Al. }, title={Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial}, journal={JAMA Oncology}, year=2019, pages={164-170} }